A driver parked his taxi to take a break in SoHo. He died behind the wheel. Then, for nearly a day, New Yorkers went about their lives — just feet from his body.
NYS Entity Status
NYS Filing Date
AUGUST 29, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - ACTUALIZE TECHNOLOGY, INC.
AROUND THE WEB
- For 18 Hours, Cabbie Sat Dead in Front Seat
By KIM BARKER - Monday Aug 14, 2017
- A Slump in Tech Stocks That Leaves Some Investors Mystified
By LANDON THOMAS Jr. - Monday Jun 12, 2017
Shares of Netflix, Apple and other giant technology companies that have powered a market rally have taken an uncharacteristic pause.
- Pittsburgh Gets a Tech Makeover
By STEVEN KURUTZ - Saturday Jul 22, 2017
The city is newly stylish, with hyped restaurants and an Ace hotel, thanks to a steady flow of Carnegie Mellon grads who decided to stay.
- Jack Dorsey's Square Inc. May Soon Loan You Money
Tuesday Jun 27, 2017
Square Inc., the technology company best known for processing payments for small merchants across the U.S., is now angling to lend to consumers, too.
- Martin Shkreli is found guilty of fraud
By Stephanie Clifford and Colin Moynihan - Friday Aug 4, 2017
NEW YORK — Martin Shkreli, accused of defrauding his hedge fund investors and a pharmaceutical company, was convicted on three of eight counts on Friday, after a five-week trial in U.S. District Court in Brooklyn, N.Y.Shkreli was accused of securities and wire fraud related to two hedge funds he ran, MSMB Capital and MSMB Healthcare.The prosecution brought forth an “avalanche” of evidence, as prosecutor Jacquelyn Kasulis put it in her rebuttal argument, that included a threatening letter he sent to the wife of a former employee, statements he sent to MSMB investors showing great returns at the same time he had no money in fund accounts, three versions of a backdated agreement to make it look as if MSMB Capital had invested in Retrophin when it had not, as well as claims about assets under management that were wildly out of line with his actual fund size.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.